Vor Bio appoints Cumbo, Detheux to board of directors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 21 2025
0mins
Board Appointments: Vor Bio (VOR) has appointed Alexander Cumbo and Michel Detheux, Ph.D., to its Board of Directors, effective July 16, 2025.
Current Positions: Alexander Cumbo is the President and CEO of Solid Biosciences, while Michel Detheux, Ph.D., serves as the President and CEO of iTeos Therapeutics.
Analyst Views on SLDB
Wall Street analysts forecast SLDB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLDB is 14.29 USD with a low forecast of 9.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.660
Low
9.00
Averages
14.29
High
20.00
Current: 5.660
Low
9.00
Averages
14.29
High
20.00
About SLDB
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
